Last reviewed · How we verify
NCT04546919
Effect of R-spondin3 on Sepsis Induced Endothelial Dysfunction
trial testing sepsis in Acute Lung Injury (ALI) in 60 participants. Status unknown.
8 August 2021
Quick facts
| Lead sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 8 July 2020 |
| Primary completion | 8 August 2021 |
| Estimated completion | 12 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- sepsis
Conditions studied
- Acute Lung Injury (ALI) — all drugs for Acute Lung Injury (ALI) →
- Acute Respiratory Distress Syndrome (ARDS) — all drugs for Acute Respiratory Distress Syndrome (ARDS) →
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Who can join
18 and older, any sex, with Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sepsis is the most frequent risk factor for ALI/ARDS. Meanwhile, Pulmonary is the most vulnerable organ to fail in response to sepsis, vascular endothelial dysfunction is a central event in the pathophysiology of sepsis. An improved understanding of endothelial response and associated biomarkers may lead to strategies to more accurately predict outcome and develop novel endothelium-directed therapies in sepsis. The human and mouse R-spondins encode a family of proteins that includes four paralogs (R-spo1-4). R-spondins are secreted proteins found primarily in the extracellular region and are known to promote β-catenin signaling. Among them, the embryonic lethal vascular remodeling phenotype of R-spondin3 (Rspo3) mutant mice suggests a role of EC derived Rspo3 in angiogenesis. Rspo3 protects tissues against mesenteric I/R by tightening endothelial cell junction and improving vascular intergrity. However, the role of Rspo3 in sepsis-induced pulmonary endothelial dysfunction remains unclear. Thus, it is worthwhile to explore the relationship between Rspo3 and sepsis-induced lung injury, which will be helpful for prevention and treatment of sepsis-induced lung injury and endothelial dysfunction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04546919
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of sepsis
Trials testing the same drug.
- NCT04974411 — Establishment of Early Diagnosis and Monitoring Model for Sepsis Patients · unknown
- NCT04103268 — Neutrophil Phenotypic Profiling and Organ Injury Assessment in Patients With Sepsis · recruiting
- NCT05842980 — BIomarkers to Predict the Outcomes of Sepsis · unknown
- NCT03952390 — Effect of Renin-Angiotensin System on Platelet in Patient With Sepsis · completed
Other Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials
Trials by the same sponsor.
- NCT07506811 — Effects of Different Music Tempos on Feeding Outcomes in Preterm Infants · NA · not yet recruiting
- NCT07441187 — Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type · not yet recruiting
- NCT07375602 — A Multimodal AI Prediction Model for Complications After Transcatheter Closure of Perimembranous VSD in Children · recruiting
- NCT07405658 — Clinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Ear · not yet recruiting
- NCT07381400 — Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Stu · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04546919 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Last refreshed: 14 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04546919.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing